In many cases of neurocognitive decline, disease progression is associated with changes in proteins within the brain. Some of these changes are caused by chemicals called dicarbonyl electrophiles. A potential new supplement isolated from buckwheat, 2-hydroxybenzylamine (2-HOBA), can bind and inactivate these dicarbonyl electrophiles. Previously, 2-HOBA has been shown to be effective in preventing cognitive decline in mice. Now, researchers have tested the safety of this supplement in 18 healthy adult volunteers. Participants were administered either 2-HOBA acetate (500 or 750 mg) or a placebo 3 times a day for 2 weeks. The supplement was found to be safe and well-tolerated at both dosages: no serious adverse events were reported. Researchers can now begin a larger trial to explore the effectiveness of 2-HOBA acetate in preventing cognitive decline in humans.
Pitchford LM, et al. Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial. BMC Pharmacol Toxicol. 2020;21:3. doi:10.1186/s40360-020-0382-y.